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Autophagy provides a mechanism for the turnover of cellular organelles and proteins through a lysosome-dependent degradation
pathway. During starvation, autophagy exerts a homeostatic function that promotes cell survival by recycling metabolic
precursors. Additionally, autophagy can interact with other vital processes such as programmed cell death, inﬂammation, and
adaptive immune mechanisms, and thereby potentially inﬂuence disease pathogenesis. Macrophages deﬁcient in autophagic
proteins display enhanced caspase-1-dependent proinﬂammatory cytokine production and the activation of the inﬂammasome.
Autophagy provides a functional role in infectious diseases and sepsis by promoting intracellular bacterial clearance. Mutations in
autophagy-related genes, leading to loss of autophagic function, have been implicated in the pathogenesis of Crohn’s disease.
Furthermore, autophagy-dependent mechanisms have been proposed in the pathogenesis of several pulmonary diseases that
involve inﬂammation,including cystic ﬁbrosis and pulmonary hypertension. Strategies aimed at modulating autophagy may lead
to therapeutic interventions for diseases associated with inﬂammation.
1.Introduction
1.1. Inﬂammation. Acute inﬂammation acts as part of the
host’s innate protective response to infection or tissue injury.
Endothelial cell injury or microbial infection causes changes
in vascular permeability, local edema, and in the distribution
of chemoattractants [1, 2]. The activation of endothelial
cells allows the transmigration of leukocytes, initially pri-
marily neutrophils (polymorphonuclear (PMN) cells), to
t h es i t eo ft i s s u ei n j u r y[ 3]. Finally, macrophages uptake
apoptotic PMN cells, cellular debris, and invasive pathogens
via phagocytosis during the resolution of acute inﬂamma-
tion, which leads to neutrophil clearance and the release of
anti-inﬂammatory cytokines such as transforming growth
factor-β1. The resolution program ends with the eﬄux
of macrophages from the site of inﬂammation through
lymphatics [4]. However, aberrant inﬂammatory responses
can be associated with a wide range of acute, chronic,
and systemic inﬂammatory disorders, such as cardiovascular
disease, asthma, inﬂammatory bowel disease, rheumatoid
arthritis [1], and cystic ﬁbrosis [5].
In recent years, emerging evidence has indicated that the
process of macroautophagy may play an essential role for the
host during bacterial clearance [6]a sw e l la si n t e r a c tw i t hi n -
ﬂammatory processes, and thereby potentially impact the
outcome of disease progression.
1.2. Autophagy. Macroautophagy (autophagy) refers to the
cellular pathway for the degradation or disposal oforganelles
and proteins vialysosomal processes. The autophagy mecha-
nism involves double-membrane vesicles, called autophago-
somes or autophagic vacuoles (AVs) that target and engulf
cytosolic material, which may include damaged organelles
or denatured proteins. The autophagosomes fuse with lyso-
somes to form single-membrane autolysosomes. Lysosomal
enzymes facilitate this degradation process to regenerate
metabolic precursor molecules (i.e., amino acids and fatty2 International Journal of Cell Biology
acids), which can be used for anabolic pathways and energy
production [7–12]. This process may thereby prolong cellu-
lar survival during starvation. During infection, autophagy
assistsintheimmuneresponsebyprovidingamechanism for
the intracellular degradation of invading pathogens such as
bacteria[5].Furthermore,autophagyinﬂuencestheimmune
system during pathogen clearance by regulating antigen pre-
sentation, lymphocyte development, and proinﬂammatory
cytokine production [13]. However, the mechanism for the
involvement of autophagy in cytokine secretion remains
poorly understood. In addition to macroautophagy, several
other subtypes of autophagy exist, including microau-
tophagy and chaperone-mediated autophagy [14].
At least 30 autophagy-related (Atg) genes have been de-
termined, primarily in yeast. The homologues of many of
these Atg geneshave beenshown to participate in the regula-
tionofautophagy[14–16].Amongthese, Beclin1(themam-
malianhomologofyeastAtg6)representsamajorautophagic
regulator and tumor suppressor protein [17].
Recentstudiessuggestthatautophagyevolvedasa home-
ostatic response for unicellular eukaryotic organisms. More-
over, the same autophagy process could be used for diverse
functions in more complex multicellular organisms in re-
sponse to various stressful stimuli [5]. Therefore, the evolv-
ing understanding of autophagy and its interaction with
otherintracellular processes may reshape ourknowledge and
lead to the development of therapies for inﬂammatory
disorders.
Recent studies suggest that the process of autophagy may
be more selective than originally described such that there
exist speciﬁc molecular mechanisms that regulate the auto-
phagy-dependentintracellulardegradationofbacteria,dena-
tured protein aggregates, mitochondria, and other subcellu-
lar substrates [18]. Autophagyplays an important role in the
maintanance of healthy organelle populationsby eliminating
damaged specimens (e.g., mitochondria and endoplasmic
reticulum (ER)).
In addition to providing basic homeostatic functions,
autophagy can potentially impact other vital cellular pro-
cesses, including programmed cell death (i.e., apoptosis).
The complex relationship between autophagy and cell death
pathwayshas beenreviewed elsewhere [19–21].Itisnow well
recognized that autophagy can exert a critical inﬂuence on
systemic immune and inﬂammatory responses and on the
speciﬁc cell types that mediate these responses. This paper
will summarize how these dynamic relationships inﬂuence
the pathogenesis of several diseases, including pulmonary
and systemic diseases, where inﬂammatory processes have
been implicated.
1.3. Autophagic Machinery. The activation of the autophagic
pathway involves the assembly of several macromolecular
signaling complexes [14, 16]. These include the mammalian
target of rapamycin (mTOR) complex-1 (mTORC1) which
consists of mTOR and several accessory proteins. The
mTORC1 regulates a macromolecular substrate complex
(mTOR substrate complex) containing the mammalian un-
coordinated-51-like protein kinase ULK1 (the mammalian
homologofyeastAtg1)andotherfactors(i.e.,Atg13,FIP200,
and Atg101) [22–25]. The mTOR pathway negatively reg-
ulates autophagy during nutrient-rich conditions. Through
this pathway, starvation and stimulation with the immuno-
suppressive drug rapamycin potently induce autophagy, by
inhibiting mTOR kinase activity, and thereby permitting the
activation of ULK1 kinase, a major initiator of autophagy
[26, 27].
The de novo formation of the autophagosome mem-
brane, presumably originating from the ER, requires a major
macromolecular regulatory complex that includes Beclin
1 and Vps34, a Class III phosphatidylinositol-3-kinase
(PIK3C3) [28]. Several additional proteins can interact with
and inﬂuence the activity of this complex (e.g., Rubicon,
UVRAG, and Bcl-2 family proteins, etc.). Activation of
PIK3C3 activity leads to the increased production of phos-
phatidylinositol-3-phosphate (PI-3P) which regulates the
initial steps in autophagosome formation [28].
The subsequent elongation of autophagosomes requires
the activation of two ubiquitin-like conjugation systems [14,
16, 30]. First, the ubiquitin-like protein Atg12 is conjugated
to Atg5 by Atg7 (E1-like) and Atg10 (E2-like) enzymes. The
Atg5–Atg12 complex in turn associates with Atg16L (the
mammalian homolog of yeast Atg16). The resulting multi-
meric complex assists in the elongation of the autophagic
membrane [30].
A second conjugation system requires the ubiquitin-
like protein, microtubule-associated protein-1 light chain 3
(LC3), and the mammalian homologue of yeast Atg8 [31,
32]. Several homologues of LC3 (i.e., LC3B) and related cel-
lular cognate proteins (i.e., GABARAP) are conjugated with
the phospholipid phosphatidylethanolamine (PE) [32, 33].
Atg4B catalyzes the proteolytic processing the LC3 proform
to generate the cleaved form LC3-1. Conjugation of LC3-I
with PE is subsequently catalyzed by Atg7 (E1-like) and Atg3
(E2-like)activities [30]. Inmammals, theconversionofLC3-
I(unconjugatedform)toLC3-II(lipidatedform)isgenerally
regarded asakeyregulatory stepand indicatorofautophago-
some formation [32]. In the ﬁnal stages of autophagy, the
autophagosome matures and fuses with the lysosome, where
encapsulatedcargoesaredigestedbyresidenthydrolaseactiv-
ities [9]. Autophagosome maturation and fusion are assisted
by several additional regulatory proteins, including small
GTPases and lysosome-associated membrane proteins (i.e.,
LAMP2) [14, 34, 35].
Recently, additional proteins (i.e., p62SQSTM1,N B R 1 ,
NDP52,Nix,andothers)havebeenidentiﬁedintheselection
of autophagic cargo. Collectively, these proteins, which are
selectively degraded by autophagosomes, act as autophagic
adaptors, or cargo receptors for prospective cargos including
ubiquitinatedproteins, bacteria, or mitochondria [18]. To be
considered as an active process, autophagy requires the com-
pletion of all steps of the autophagic pathway including
substrate turnover, which are collectively referred to as auto-
phagicﬂux [35]. ChangesinLC3B expression and/orconver-
sion, or accumulations of autophagosome numbers, do not
necessarily represent active autophagy, as these conditions
can arise if the autophagosome-lysosome fusion event and/
or subsequent lysosomal processing steps are blocked or








Figure 1:The “macroautophagic”pathwayresponds to stimulationby variousenvironmentalcues includingnutrient availabilityornoxious
agents, which result in the accumulation of damaged proteins and/or organelles as well as pathogenic bacteria or viral infection. In the
nucleation phase, a preautophagosomal structure develops from subcellular membranes and subsequently evolves into the phagophore
or isolation membrane. The isolation membrane then expands to surround and engulf a cytoplasmic “cargo” of material targeted for
degradation, culminating in double-membraned autophagosomes. Finally, the fusion of autophagosomes with lysosomes results in the
formation of the autolysosome. During the degradative phase of autophagy, the encapsulated contents of autolysosomes are digested by
lysosomal degradative enzymes (e.g., cathepsins and other acid hydrolases). The digested contents are then released to the cytosol for
reutilization in anabolic pathways.
2.InteractionofAutophagywithInﬂammation
and Immune Responses
2.1. Autophagy and Inﬂammatory Signaling. The signaling
pathways that regulate inﬂammatory processes now appar-
ently have a role in the regulation of autophagy and vice-
versa. In addition to classical signals such as starvation and
energy exhaustion, several pathogen-associated molecular
patterns (PAMPs) have been shown to promote autophagic
activation [6]. Recent studies suggest that Toll-like receptors
(TLR), the primary cellular sensors for PAMPs, can regulate
autophagy through the activation of downstream signaling
processes in macrophages and other cells types (reviewed
in reference [6]). For example, the TLR9 ligand, bacterial
CpG motifs, can induce autophagy in rodent and human
tumor cell lines [38]. The screening of TLR ligands for their
capacity to induce LC3 puncta (in green ﬂuorescent protein-
LC3 assays) revealed that single-stranded RNA (ssRNA) and
imiquimod, two model TLR7 ligands, were relatively potent
inducers of autophagy [39]. Bacterial LPS, a TLR4 ligand,
has been implicated in several studies as a stimulator of
autophagic signaling in cultured macrophage cell lines [39,
40]. The ability of LPS to induce autophagy in primary
macrophages, however, has been disputed [41].
Additional studies suggest that autophagic proteins can
modulate responses to viral infections. For example, the
IFN-β response to double-stranded DNA (dsDNA) is en-
hancedinmouseembryonicﬁbroblastsbygeneticdeletionof
Atg9a[42].Forexample,thedeletionofAtg5in macrophages
and murine embryo ﬁbroblastswasreported toenhance type
1 interferon production in response to ssRNA virus [43].
The ampliﬁcation of IFN responses to infection in these
cell types was attributed to loss of mitochondrial quality
control and enhanced mitochondrial ROS production in
responsetoimpairedautophagicprocessing[43].Incontrast,
independent studies reported that the IFN-α response to
infection with ssRNA virus (i.e., vesicular stomatitis virus)
was compromised in Atg5−/− chimeric mice and in Atg5−/−
dendritic cells [44]. Independently of autophagy, Atg5 was
also shown to play a role in resistance to the intracellular
pathogen Toxoplasma gondi by facilitating the recruitment of
a p47 GTPase to the bacteria containing vacuole [45].
Recentobservationshaverevealeda relationship between
autophagic proteins and inﬂammasome-associated proin-
ﬂammatory cytokine maturation in macrophages [41, 46,
47]. Inﬂammasomes are cytosolic multiprotein complexes
that constitute a novel inﬂammatory signaling mechanism
and which govern the maturation and secretion of select4 International Journal of Cell Biology
proinﬂammatory cytokines, such as IL-1β, IL-18, and IL-33
[48]. Cytosolic receptors of the NOD-like receptor (NLR)
family (i.e., NLRP3 and NLRP1) interact with binding
partners toform inﬂammasome complexes.NLRP3interacts
withan adaptorprotein(apoptosis-associated specklikepro-
tein containing CARD (ASC)), which recruits and activates
the procaspase-1 by proteolytic cleavage [48].
Proinﬂammatory cytokine secretion (IL-1β and IL-18)
was enhanced in atg16l1 or atg7 deleted macrophages in
response to LPS [41]. In contrast, atg16l1 or atg7 deﬁciency
did not aﬀect TNF and IFN-β production or NF-κBp a t h w a y
activation in macrophages stimulated with LPS [41]. Fur-
thermore, atg16l1-deleted mice displayed increased suscep-
tibility to a murine model of colitis, which could be amelio-
rated by anti-IL-18 therapy [41]. In recent studies, increased
activation of IL-1β and IL-18 has also been observed in
macrophages and monocytes isolated from mice genetically
deﬁcient in Beclin 1 and LC3B [46].
Cytokine activation in response to LPS and ATP in wild-
type macrophages, as well as the ampliﬁcation observed in
LC3B or Beclin 1-deﬁcient macrophages, required the
NLRP3 inﬂammasome pathway [46, 47]. The mechanism
by which autophagy deﬁciency enhanced NLRP3 inﬂam-
masome pathway activation was mediated by deregulation
of mitochondrial homeostasis, including the enhanced pro-
duction of mitochondrial ROS and increased mitochondrial
membrane permeability transition [46, 47]. The pathway
to caspase-1-dependent IL-18 secretion in macrophages was
further shown to be blocked by mitochondrial targeting
antioxidants[46].These experiments,takentogether,suggest
that autophagic proteins dampen inﬂammasome pathway
activation by stabilizing mitochondria and/or maintaining
mitochondrial quality control through autophagy. Further
research in this area may uncover additional mechanisms.
Taken together these studies suggest an important role for
autophagic proteins in the dampening of proinﬂammatory
responses, and that warrants further investigation in models
of inﬂammatory disease.
2.2. Autophagy and Adaptive Immunity. Autophagy plays
critical role in bacterial clearance mediated by autophagoso-
mal sequestration and subsequent autolysosome-dependent
degradation and in the regulation of the cytokine response
[5]( Figure 2). In addition to these roles, recent studies also
indicate that autophagy can participate in adaptive immune
responses, including antigen presentation, and in the main-
tenance of lymphocyte function [5, 49]. The discovery
that autophagosomes can fuse with and transfer content to
major histocompatibility complex (MHC) Class II loading
compartments illustrates the importance of this relationship
[50]. The immune system detects pathogen-derived antigens
(i.e., peptides) and initiates a response through MHC Class
I and II loading compartments. The peptide fragments
generated by intracellular degradation of bacteria, including
autolysosomal degradation, are displayed on MHC Class I
and II molecules. Class I MHC molecules are generally pre-
sent in most cell types and assist in antigen presentation
to CD8+ T cells. Inhibition of autophagy by chemical in-
hibitors or genetic knockdown of select autophagic proteins
(i.e., Atg5) typically does not aﬀect MHC Class I antigen
presentation [49]. However, autophagy induction in target
cellswasshown toincreasetheirabilitytoactasimmunogens
for dendritic cell cross-presentation to CD8+ T cells [51].
Furthermore, autophagy induced during HSV-1 infection
enhances the presentation of viral-derived antigen on MHC
Class I molecules [52]. Class II MHC molecules (which
are found speciﬁcally in antigen-presenting cells such as
macrophages, B cells, and dendritic cells) present bacterial
fragments toCD4+ Tcells,which mediateimmuneresponses
from other cell types. Genetic interference of Atg12 was
shown toinhibit MHCClass II antigenpresentation toCD4+
T cells during Epstein-Barr virus infection [53]. Genetic
deletion of Atg5 also suppressed the processing and presen-
tation of herpes simplex virus-2- (HSV-2-) derived antigen
on MHC Class II molecules and enhanced vulnerability of
mice to HSV-2 infection [54]. Recent studies have identiﬁed
a novel role for autophagy in the generation of a self-tolerant
T cell repertoire. Constitutively, highly expressed autophagy
in thymic epithelial cells delivers endogenous proteins to
MHC Class II molecules and contributes to CD4+ T
cell selection. The grafting of embryonic thymi from Atg5−/−
miceintoathymic nudemicewasshowntopromotesystemic
lymphoid inﬁltration [55]. Taken together, these examples
suggestthat autophagyand/orautophagicproteinsplaymul-
tivariate roles in immune system function.
3.AutophagyinInﬂammatory Diseases
3.1.Autophagyin Crohn’sDisease. Crohn’sdisease isachron-
ic inﬂammatory bowel disease characterized by inﬂamma-
tion, ulceration, and neutrophil inﬂux in the intestinal
epithelia. The pathophysiological mechanisms of Crohn’s
disease remain unclear but may involve excess inﬂammatory
responses, abnormal Paneth cell granule secretion, and im-
paired intracellular bacterial clearance [56]. Recent hu-
man studies have suggested links between autophagy and
Crohn’s diseases. Genome-wide association studies (GWAS)
have revealed small nucleotide polymorphisms (SNPs) in
autophagy genes such as ATG16lL and in additional genes
now known to inﬂuence autophagic processing (i.e., NOD2
and IRGM) associated with susceptibility to Crohn’s disease
[57–61].
The ﬁrst of these to be described, a T300A variant in
the ATG16lL gene, has been identiﬁed as an associated risk
factor for Crohn’s disease. ATG16lL plays a key role in
autophagosome formation [57, 58]. Genetic deletion of
ATG16lL impairs autophagosome formation and autophagic
processing of protein and, furthermore, promotes IL-1β
production in macrophages in response to LPS stimulation
[41]. The mechanism by which the T300A mutation in
ATG16lL compromises autophagic function remains unclear
[6].
Variantsinthegeneencodingimmunity-related p47gua-
nosine triphosphatase (IRGM) were associated with Crohn’s
disease in a recent GWAS [62]. Its murine homologue Irgm1
can regulate intracellular autophagy in response to IFN-γ

























Figure 2: Autophagy as an adaptive cellular process potentially impacts the progression of inﬂammatory diseases by several possible
mechanisms.(i) Autophagy, by acting as a “xenophagic”response, directly participates inbacterial clearance, throughthe encapsulationand
lysosomal delivery of invading bacteria for degradation. (ii) Autophagic processes can assist in antigen presentation through the digestion
of invading pathogens. (iii) Autophagic proteins play a role in the dampening proinﬂammatory responses, including proinﬂammatory
cytokine secretion, through the maintenance of mitochondrial quality. (iv) Autophagic degradation of denatured protein aggregates may
play a protective role in tissues such that impaired function has been associated with diseases such as cystic ﬁbrosis [5]. (v) Autophagic
protein LC3B potentially regulates other cellular processes as recently described in a model of hypoxia-induced pulmonary hypertension. In
these studies, LC3B was found to inhibit vascular cell proliferation and promote smooth muscle cell apoptosis, collectively associated with
protection in this model [29].
displayed an impaired ability to clear intracellular bacteria
[63]. Recent studies suggest that human IRGM regulates
autophagy through dynamic interactions with mitochondria
[64, 65]. IRGM associates with mitochondria by binding
to the phospholipid cardiolipin, a constituent of the mito-
chondrial inner membrane, and consequently promotes
mitochondrial membrane depolarization and mitochondrial
ﬁssion [65].
At least three mutations in the gene encoding nu-
cleotide-binding oligomerization domain 2 (NOD2), also
known as CARD15, including small nucleotide polymor-
phisms (R702W and G908R) and a frameshift mutation
(L1007fsinsC) have been found in association with Crohn’s
disease [66–73]. NOD2, a protein of the NLR family, func-
tions as an intracellular bacteria sensor. NOD2 activates
signaling pathways in response to stimulation with bacteria-
derived peptides [74]. Muramyl dipeptide (MDP), a compo-
nent of the bacterial peptidoglycan cell wall, induces auto-
phagy in intestinal epithelial cells, and thereby also promotes
autophagy-dependent bacterial clearance [75]. The induc-
tion of autophagy by MDP requires NOD2 and ATG16L and
involves physical interaction of NOD2 with ATG16L [76].
N O D 2r e c r u i t sA T G 1 6 Lt ot h em e m b r a n es i t eo fb a c t e r i a l
entry and facilitates association of LC3B with bacteria [76].
The expression of NOD2 genetic variants associated with
Crohn’s disease results in impaired autophagic processing of
pathogens (i.e., Salmonella typhimurium) by epithelial cells
in response to treatment with NOD2ligand [75].In addition
to stimulation of autophagy-dependent bacterial clearance,
NOD2 was recently shown to also regulate dendritic cell
MHC Class 2 dependent antigen presentation to CD4+ T-
cells [77]. Recent studies also show that inhibition of the
autophagyprocessor expression ofthe ATG16lLT300A vari-
ant leads to increased proinﬂammatory cytokine responses
(i.e., IL-1β and IL-6) in human primary immune cells in
response to stimulation with NOD2 ligands [78].
Takentogether,defectsofautophagicactivity astheresult
of mutations in autophagy-associated genes (i.e., ATG16L1
and IRGM) and bacterial sensors (NOD2) have been asso-
ciated with the impaired clearance of harmful bacterial
species associated with Crohn’s disease, impaired antigen
presentation, and also with the higher production of proin-
ﬂammatory cytokines implicated in the pathogenesis of
Crohn’s disease.6 International Journal of Cell Biology
3.2.AutophagyinRespiratoryInfections. Autophagycanexert
antibacterial and antipathogen functions, which were origi-
nallydemonstratedinseveralinfectiousdisease modelsusing
live bacteria [79, 80]. The general role of autophagy in host
defense against various microbes including bacteria, viruses,
and parasites has now been widely recognized [6].
Phagocytosis of nonpathogenic mycobacteria by macro-
phages leads to autophagy and apoptosis, which results in
the termination of the microbe. However, phagocytosis of
pathogenic mycobacteria inhibits the autophagy pathway
with the acidiﬁcation of phagosomes and lysosomal fusion
[81]. Mutations in NOD2, a pathogen-recognition receptor
critical for bacterial autophagy [76, 77], are associated with
vulnerability to microbial infection with the etiologic agent
of leprosy, Mycobacterium leprae [82].
In the case of M. tuberculosis, the mycobacteria remains
and replicates in immature phagosomes. In addition, instead
of stimulating macrophage apoptosis, phagocytosis of M.
tuberculosis promotes necrotic cell death, which promotes
bacteria dispersal to uninfected cells. As a result, reduced
mycobacterial antigen presentation and chronic M. tuber-
culosis infection occur [83]. However, experimental stimu-
lation of autophagy can reduce intracellular replication and
survival of M. tuberculosis [79, 83–85]. Conversely, chemical
inhibitors of autophagy promote infection [80, 86].
IFN-γ production makes an important contribution to
host defense against M.tuberculosis. Macrophagesstimulated
with IFN-γ induce autophagy, and this response facilitates
the resolution of infection [80, 87]. IFN-γ-stimulation
can thereby bypass the inhibition of lysosomal fusion of
virus containing phagosomes, leading to the destruction of
the organism by p62SQSTM1-dependent selective autophagy
[87], and resolution of infection. IFN-γ induced autophagy
involves the p47 guanosine triphosphatase IRGM-1 [64,
65, 80, 88]. Interestingly, small nucleotide polymorphisms
occurring in the IRGM-1 gene, as implicated in Crohn’s
disease,wererecentlyalsolinkedtoincreasedsusceptibilityto
M. tuberculosis infection [89, 90]. Finally, autophagicprocess
may assist in the generation of antivirulence factors against
this organism through degradation of substrate proteins
[87, 91].
Giventhat M.tuberculosisisthepathogenicagentcausing
tuberculosis, this bacterium is a major contributor to global
disease burden [92]. Therefore, therapeuticstrategies involv-
ingautophagypathwaymanipulationtoreduceinfectionand
promote adaptive immunity to this organism, and to other
related pathogens, may be of considerable interest. Addi-
tional studies implicate autophagy in defense against other
respiratory pathogens, such as Legionella pneumophila,t h e
causative agentin Legionnaire’s disease. Forexample, genetic
deﬁciency of atg9 was shown to promote the growth of
Legionella pneumophila, which suggests a role of autophagy
in defense against this organism [93, 94].
Recent studies have shown that the fundamental mech-
anisms of host pathogenic response are conserved in lower
eukaryotes [95–97]. Also, autophagy remains critical for
normal cellular development of the social amoeba in Dic-
tyostelium discoideum [98]. Therefore, D. discoideum has
becomea widely used model system for the study of bacterial
infection and autophagy [99–101]. Infection of D. dis-
coideum with Legionella pneumophila causes a large increase
in diﬀerentiallyregulated autophagy-relatedgenes, including
ATG8, ATG9, and ATG16 [102]. However, recent studies
have shown that L. pneumophila can undergo replication in
autophagy mutants of D. discoideum [103].
3.3. Autophagy in Sepsis. Sepsis remains a leading cause of
mortality in intensive care units. This condition arises as a
consequence of systemic responses to inﬂammation caused
byacquiredbacterial,fungal, parasitic,orviralinfectionsand
may lead to multiple organ failure [104].
To date, little is known of the role of autophagy in sepsis.
Marked autophagosome accumulation has been observed in
t h el i v e r so fp a t i e n t sw h od i ef r o ms e p s i s[ 105]. However,
it currently remains unclear whether this observation repre-
sents increased autophagicactivity (ﬂux)in sepsis patients or
inhibition of autophagic processing which leads to the inap-
propriate accumulation of autophagosomes. Genetic dele-
tion of critical autophagic proteins has recently been shown
to increase sepsis-induced inﬂammatory responses in mice
subjected to the cecal-ligation and puncture (CLP) model
of polymicrobial sepsis [46]. Similar results were observed
in mice challenged with LPS injection [46]. Furthermore,
BECN1+/− mice and LC3B−/− mice were found to be suscep-
tible to the lethal eﬀects septic shock in mice, and to express
higher levels of IL-18, one of the inﬂammasome-associated
cytokines in the plasma [46]. Collectively, these studies sug-
gest a potential link between autophagy and inﬂammatory
responses during the pathogenesis of sepsis.
4.AutophagyinPulmonaryDisease
Recent evidence from this laboratory and other, suggests that
autophagy may be critically involved in other noninfectious
pulmonary diseases, where inﬂammation has been im-
plicated.In thesecases, additional functional aspects of auto-
phagy may indirectly aﬀect inﬂammation by limiting tissue
injury. In two illustrative examples, we describe recent work
illustrating how autophagy may impact the pathogenesis of
pulmonary hypertension and cystic ﬁbrosis.
4.1. Role of Autophagic Protein LC3B in Pulmonary Hyper-
tension. Recent studies from this laboratory have sought to
determine the involvement of autophagic proteins in pul-
monary arterial hypertension (PAH). PAH is a complex dis-
ease of varying etiologies which include idiopathic and
forms as well as other subtypes (i.e., associated with left
heart disease, HIV infection, etc.). PAH is characterized
mainly by vasoconstriction, increased pulmonary artery
pressure, thickening and ﬁbrosis of the artery, which may
lead to cardiac dysfunction, and right ventricular hyper-
trophy [106, 107]. We examined the prospective role of
autophagic proteins in an experimental mouse model of
chronic hypoxia-induced pulmonary hypertension. Expo-
sure to chronic hypoxia in mice resulted in the increased
expression of LC3B and its conversion of LC3B-II in
the lung. Increased LC3B staining was also observed inInternational Journal of Cell Biology 7
small pulmonary vessels of animals subjected to hypoxia.
Moreover, hypoxic lungs contained elevated numbers of
autophagosomes,asdetectedbyelectronmicroscopy.Impor-
tantly,micegeneticallydeletedforLC3B(LC3B−/−)displayed
increased indices of pulmonary hypertension, including
increased right ventricular systolic pressure, and Fulton’s
Index relative to wild-type mice, after chronic hypoxia [29].
These results identiﬁed an endogenous role for autophagic
protein LC3B in the regulation of protective processes
duringthedevelopmentofpulmonaryhypertension.Genetic
deletion of LC3B aggravated the hypertensive phenotype
as the result of hypoxia exposure. These observations were
corroborated with observations in vitro of increased vascular
cell (i.e., endothelial and smooth muscle) proliferation and
impairedsmooth musclecellapoptosisinafterLC3B-speciﬁc
genetic knockdown. These experiments, which have used
LC3B knockout or knockdown strategies, suggest a speciﬁc
role for the autophagic protein LC3B, in vascular responses
to hypoxia, and associated pathogenic processes implicated
in the development of pulmonary hypertension. However,
these experiments did not unequivocally establish a speciﬁc
role for autophagic activity in these phenotypes. The authors
could not exclude that LC3B exerts eﬀects on signaling
processes independently of the process of autophagy. In
contrast, the vascular changes recorded in Beclin 1+/− mice
were not statistically signiﬁcant. Experiments using addi-
tional autophagy protein knockout mice (i.e., Atg5) may be
warranted.
The relevance of these ﬁndings to clinical disease, was
supported bysimilar observationsinhuman tissuesfrom pa-
tients with pulmonary hypertension. Human lung tissue
isolated from patientswith pulmonary hypertension (PH)of
various etiologies, including PAH, displayed increases in the
totalexpressionofLC3B,andinthelevelsofitsactivated(PE-
conjugated) form LC3B-II, when compared to lung tissue
frompatientsfreeofpulmonaryvasculardisease.Theexpres-
sion of LC3B was markedly increased in the endothelial
cell layer, as well as in the adventitial and medial regions
of large and small pulmonary resistance vessels from PH
lung, relative to normal vascular tissue. These results, taken
together, suggest that autophagic proteins may potentially
be exploited for the prevention and/or treatment of vascular
disease in humans [29].
4.2. Autophagy in Cystic Fibrosis: A Role for “Aggrephagy”. In
addition to eﬀects on bacterial clearance and the resolution
of inﬂammation, autophagy may exert additional functions
that could ameliorate inﬂammatory diseases. One of these
functions is the selective clearance of aggregated and dena-
tured protein, a process termed “aggrephagy”. This function
is exempliﬁed by recent studies on the role of autophagy
in cystic ﬁbrosis (CF), a debilitating autosomal recessive
disorder. CF patients are marked by the collection of mis-
folded proteins in the airway epithelia due to mutations
(ΔF508 and others) in the gene encoding the cystic ﬁbrosis
transmembrane conductance regulator (CFTR) [1].
The pathological features of CF include aberrant accu-
mulation of hyperviscous mucous in the airways, impaired
mucociliary clearance, and increased inﬂammation. Lung
injury may also arise from secondary infections (i.e., Staphy-
lococcus aureus, Pseudomonas aeruginosa, etc.) [108].
Recent studies demonstrate that human airway epithelial
cells from CF patients, which bear the mutation in the CFTR
gene, have an impaired autophagic response. In response to
starvation, a classical inducer of autophagy, these cells ex-
hibited reduced autophagosome formation and accumula-
tion of p62SQSTM1. The human epithelial cells with CFTR
mutationalsodisplayedanabnormalaccumulationofpolyu-
biquitinated protein aggregates indicative of impaired aggre-
some clearance. In normal epithelial cells, mutation and/or
loss of function of CFTR was associated with elevated
reactive oxygen species (ROS) production and increased
tissue transglutaminase 2 (TG2) levels, an important factor
ofinﬂammatory responseinCF.Activationofthesepathways
caused aloss offunction inBeclin1and theBeclin1/PIK3C3
complexand,asaresult,lossofautophagicfunction.Beclin 1
overexpression, or the application of cystamine or other
antioxidants restored Beclin 1 function and autophagy and
reverted the CF airway phenotype in human CF nasal
biopsies,i nv i v oin Scnn1b-transgenic mice (a model of
CF), and CftrF508del homozygous mice as well as in cells
expressing mutant CFTR (ΔF508) in vitro. Reconstitution
of Beclin 1 levels also restored the membrane traﬃcking of
mutant CFTR and reduced its accumulation in aggresomes.
Furthermore, recent studies have shown that the accumu-
lation of p62SQSTM1, an LC3-binding and ubiquitin-binding
protein, in the context of impaired autophagy, promotes
the aberrant accumulationofintracellular protein aggregates
in human CF airway epithelial IB3-1 cells. Thus, defective
CFTR causes impaired autophagy processing, which favors
the accumulation of aggresomes, and lung inﬂammation
[5, 109]. In conclusion, selective targeting the autophagic
pathway may be included in the design of therapeutics for
the treatment of CF.
5.Final Remarks
Current studies indicate that autophagic processes can exert
a signiﬁcant impact on the regulation of inﬂammation, on
the resolution of infection, and on immune responses to
invading pathogens. These observations collectively impli-
cate autophagy as an important modulator of disease patho-
genesis. The bacterial clearing function of autophagy may
contribute to host defenses in diseases involving bacteria,
such as sepsis, inﬂammatory diseases of the bowel, and
respiratory infections. Furthermore, autophagy may serve a
function in downregulating proinﬂammatory cytokine pro-
duction implicated in tissue injury, which may also exert
a protective role in inﬂammatory diseases not necessarily
involving bacterial infection. The ability of autophagy to
clearaggregated protein (i.e.,aggrephagy) as well as to main-
tain mitochondrial homeostasis (i.e., mitophagy) may also
play supporting roles in protection against diseases associ-
ated with inﬂammation. Finally, the possibility remains that
autophagic proteins may regulate cellular processes inde-
pendently of their role in regulating autophagic activation.
Much progress has accumulated in understanding these8 International Journal of Cell Biology
relationships in select infectious and inﬂammatory diseases.
Further research will determine whether the autophagic
pathway can be manipulated for therapeutic gain in the
treatment of inﬂammatory diseases and/or other diseases of
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